{
    "clinical_study": {
        "@rank": "139567", 
        "arm_group": [
            {
                "arm_group_label": "Methylphenidate", 
                "arm_group_type": "Experimental", 
                "description": "Methylphenidate (TEVA-METHYLPHENIDATE ER-C)\nDosage:  18 mg/day at Week 1; 36 mg/day at Week 2; 54 mg/day at Week 3; 72 mg/day at Week 4. Dosage levels may be maintained or decreased to manage medication side effects.\nDosage form: tablet\nDosage frequency: daily\nDuration: 12 weeks total"
            }, 
            {
                "arm_group_label": "Cognitive Behavioral Therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Cognitive Behavioral Therapy\n12 individual 50-minute appointments over the course of up to 14 weeks\nAccording to Fairburn, Marcus, and Wilson (1993)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether methylphenidate is effective in the\n      treatment of binge eating disorder, in a randomized controlled trial extended release\n      methylphenidate versus cognitive behavioral therapy for binge eating disorder in overweight\n      or obese adult females."
        }, 
        "brief_title": "A Comparison of Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Binge Eating Disorder", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Binge-Eating Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Bulimia", 
                "Binge-Eating Disorder", 
                "Eating Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "Fifty-six adult female outpatients with binge eating disorder will receive 12 weeks of\n      methylphenidate (dosage 18-72 mg) or 12 sessions of manualized cognitive behavioral therapy.\n      Participants will complete interviewer-rated and self-report measures of eating, mood,\n      attention, and personality features before treatment, after 6 weeks of treatment,\n      immediately after treatment is completed, and 3 months after treatment is completed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of Binge-Eating Disorder according to the Diagnostic and\n             Statistical Manual of Mental Disorders, Fifth Edition\n\n          -  Body Mass Index \u2265 25\n\n          -  Must be fluent in English\n\n          -  Must be capable to give informed consent\n\n        Exclusion Criteria:\n\n          -  Current pregnancy or lactation\n\n          -  Psychotherapy or behavioural treatment for eating or weight initiated during the past\n             month\n\n          -  Psychotropic or investigational medications initiated / changed during the past three\n             months\n\n          -  Concomitant use of another psychostimulant\n\n          -  Current mental disorders that are acute/unstable, that require alternate treatment,\n             and/or that preclude ability to complete research protocol including mania,\n             psychosis, substance use (alcohol or drugs), dementia, organic brain disorders,\n             mental retardation\n\n          -  Current severe suicidality or homicidality\n\n          -  Current uncontrolled medical conditions that affect weight or BED symptoms or that\n             are contraindicated for methylphenidate including metabolic, neurological, hepatic,\n             renal, cardiovascular, hematological, ophthalmic, or endocrine diseases\n\n          -  Other serious medical illness or event such as acute myocardial infarction or stroke\n             during the past six months\n\n          -  History of seizures or tics in the past year\n\n          -  Diagnosis or family history of Tourette's\n\n          -  Clinically relevant laboratory results, including: Tachycardia as indicated by heart\n             rate > 110; Hypertension as indicated by blood pressure parameters > 140 (systolic)\n             and 90 (diastolic); Arrhythmias or conduction abnormalities as indicated by ECG\n             parameters QTC> 460msec, QRS>120 msec, and PR>200 msec; Abnormal laboratory results\n             (e.g., hypokalemia) as indicated by values > 20% above the upper range of the\n             laboratory standard of a basic metabolic screen\n\n          -  Current medications that affect weight\n\n          -  Current medications that are contraindicated for methylphenidate"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921582", 
            "org_study_id": "044/2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Methylphenidate", 
                "description": "Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.\nIntervention will consist of medication as well as components of \"Med-Plus\" treatment (e.g., medication management, general support, and compliance enhancement strategies).", 
                "intervention_name": "Methylphenidate", 
                "intervention_type": "Drug", 
                "other_name": "TEVA-METHYLPHENIDATE ER-C"
            }, 
            {
                "arm_group_label": "Cognitive Behavioral Therapy", 
                "description": "Cognitive Behavior Therapy will include three phases:\nPhase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;\nPhase 2 aims to reduce food intake and restructure eating-related cognitions;\nPhase 3 focuses upon relapse prevention", 
                "intervention_name": "Cognitive Behavioral Therapy", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methylphenidate"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "link": {
            "description": "Information about research at the Centre for Addiction and Mental Health", 
            "url": "http://www.camh.ca/research"
        }, 
        "location": {
            "contact": {
                "email": "lena.quilty@camh.ca", 
                "last_name": "Lena C Quilty, PhD", 
                "phone": "416-535-8501", 
                "phone_ext": "34313"
            }, 
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5T 1R8"
                }, 
                "name": "Centre for Addiction and Mental Health"
            }, 
            "investigator": [
                {
                    "last_name": "Lena C Quilty, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Allan S Kaplan, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Comparison of Osmotic Release Oral System Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Obese Patients With Binge Eating Disorder", 
        "overall_contact": {
            "email": "lena.quilty@camh.ca", 
            "last_name": "Lena C Quilty, PhD", 
            "phone": "416-535-8501", 
            "phone_ext": "34313"
        }, 
        "overall_contact_backup": {
            "email": "daniela.avila@camh.ca", 
            "last_name": "Daniela Avila Murati, HBSc", 
            "phone": "416-535-8501", 
            "phone_ext": "36891"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre for Addiction and Mental Health", 
                "last_name": "Lena C Quilty, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre for Addiction and Mental Health", 
                "last_name": "Allan S Kaplan, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency of binge episodes/days, as assessed by prospective daily binge diary", 
            "safety_issue": "No", 
            "time_frame": "After 12 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921582"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre for Addiction and Mental Health", 
            "investigator_full_name": "Lena Quilty", 
            "investigator_title": "Independent Scientist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency of objective binge episodes and overall illness severity, as assessed by both the Eating Disorder Examination Interview and Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of treatment"
            }, 
            {
                "measure": "Clinician impression of illness severity and improvement, as assessed by the Clinical Global Impression scale", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of treatment"
            }, 
            {
                "measure": "Quality of life, as assessed by the Quality of Life Inventory", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of treatment"
            }, 
            {
                "measure": "Associated features of binge eating as captured by the Dutch Eating Behavior Questionnaire and Binge Eating Scale", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of treatment"
            }, 
            {
                "measure": "Body Mass Index", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of treatment"
            }
        ], 
        "source": "Centre for Addiction and Mental Health", 
        "sponsors": {
            "collaborator": {
                "agency": "Ontario Mental Health Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Centre for Addiction and Mental Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}